Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis

Clinical and Vaccine Immunology

Volumn 19, Issue 1, 2012, Pages 37-44

  Parlane, Natalie A ^a,b   Grage, Katrin ^b   Mifune, Jun ^b   Basaraba, Randall J ^c   Wedlock, D Neil ^a   Rehm, Bernd H A ^b   Buddle, Bryce M ^a  

^a AGRESEARCH GRASSLANDS   (New Zealand)

^b MASSEY UNIVERSITY   (New Zealand)

^c Department of Ecosystem Science and Sustainability   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MYCOBACTERIUM ANTIGEN; PHOSPHATE BUFFERED SALINE; POLY(3 HYDROXYBUTYRIC ACID); POLYESTER; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; IMMUNE RESPONSE; INFECTION PREVENTION; LACTOCOCCUS LACTIS; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN CELL; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; TUBERCULOSIS; WILD TYPE;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ESCHERICHIA COLI; FEMALE; HYDROXYBUTYRATES; IMMUNITY, CELLULAR; LACTOCOCCUS LACTIS; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED C57BL; MICROSPHERES; POLYESTERS; RECOMBINANT FUSION PROTEINS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84855656380     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05505-11     Document Type: Article

References (56)

1. Abel B, et al. 2010. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181:1407-1417.
2. Andersen P, Doherty TM. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656-662. (Pubitemid 41052152)
3. Atwood JA, Rehm BHA. 2009. Protein engineering towards biotechnological production of bifunctional polyester beads. Biotechnol. Lett. 31:131-137.
4. Bäckström BT, Brockelbank JA, Rehm BHA. 2007. Recombinant Escherichia coli produces tailor-made biopolyester granules for applications in fluorescence activated cell sorting: functional display of the mouse interleukin-2 and myelin oligodendrocyte glycoprotein. BMC Biotechnol. 7:3.
5. Bahey-El-Din M, Gahan CGM. 2011. Lactococcus lactis-based vaccines: current status and future perspectives. Hum. Vaccin. 7:106-109.
6. Bahey-El-Din M, Gahan CGM, Griffin BT. 2010. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr. Gene Ther. 10:34-45.
7. Belisle JT, et al. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-1422. (Pubitemid 27235411)
8. Bergstedt W, et al. 2010. First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS One 5:e11277.
9. Borges O, et al. 2008. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol. 8:1773-1780.
10. Brandl H, Gross RA, Lenz RW, Fuller RC. 1988. Pseudomonas oleovorans as a source of poly(beta-hydroxyalkanoates) for potential applications as biodegradable polyesters. Appl. Environ. Microbiol. 54:1977-1982.
11. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. 2000. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:791-795. (Pubitemid 30056537)
12. Buddle BM. 2010. Tuberculosis vaccines for cattle: the way forward. Expert Rev. Vaccines 9:1121-1124.
13. Comas I, et al. 2010. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 42:498-503.
14. Cosivi O, et al. 1998. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg. Infect. Dis. 4:59-70. (Pubitemid 28347416)
15. Deng YH, Sun Z, Yang XL, Bao L. 2010. Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis. Scand. J. Immunol. 72:332-338.
16. Esen M, et al. 2009. Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 27:6862-6868.
17. Freches D, et al. 2011. Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice. Clin. Vaccine Immunol. 18:95-104.
18. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64:16-22. (Pubitemid 26009335)
19. Jahns AC, Rehm BHA. 2009. Tolerance of the Ralstonia eutropha class I polyhydroxyalkanoate synthase for translational fusions to its C terminus reveals a new mode of functional display. Appl. Environ. Microbiol. 75: 5461-5466.
20. Kaufmann SHE, Hussey G, Lambert P-H. 2010. New vaccines for tuberculosis. Lancet 375:2110-2119.
21. Khader SA, et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:369-377. (Pubitemid 46745412)
22. Launois P, et al. 1994. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 62:3679-3687.
23. Liang MT, Davies NM, Blanchfield JT, Toth I. 2006. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv. 3:379-388. (Pubitemid 44534050)
24. Lin Y, Slight S, Khader S. 2010. Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. 32:79-90.
25. Lu J, et al. 2011. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin. Dev. Immunol. 2011:617892.
26. Majlessi L, et al. 2005. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J. Immunol. 174:3570-3579. (Pubitemid 40354066)
27. McShane H, et al. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244. (Pubitemid 39540442)
28. Mifune J, Grage K, Rehm BHA. 2009. Production of functionalized biopolyester granules by recombinant Lactococcus lactis. Appl. Environ. Microbiol. 75:4668-4675.
29. Mittrücker HW, et al. 2007. Poor correlation between BCG vaccinationinduced T cell responses and protection against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 104:12434-12439.
30. Morello E, et al. 2008. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. J. Mol. Microbiol. Biotechnol. 14:48-58. (Pubitemid 350022332)
31. Mullaney JA, Rehm BHA. 2010. Design of a single-chain multi-enzyme fusion protein establishing the polyhydroxybutyrate biosynthesis pathway. J. Biotechnol. 147:31-36.
32. Newman KD, Samuel J, Kwon G. 1998. Ovalbumin peptide encapsulated in poly(D,L lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control. Release 54:49-59. (Pubitemid 28255237)
33. Ordway D, et al. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid downregulation. J. Immunol. 179:522-531. (Pubitemid 46986569)
34. Orme IM. 2011. Development of new vaccines and drugs for TB: Limitations and potential strategic errors. Future Microbiol. 6:161-177.
35. Parida SK, Kaufmann SHE. 2010. Novel tuberculosis vaccines on the horizon. Curr. Opin. Immunol. 22:374-384.
36. Parlane NA, et al. 7 October 2011, posting date. Production of a particulate hepatitis C vaccine candidate by engineered Lactococcus lactis. Appl. Environ. Microbiol. doi:10.1128/AEM.06420-11.
37. Parlane NA, Wedlock DN, Buddle BM, Rehm BHA. 2009. Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents. Appl. Environ. Microbiol. 75:7739-7744.
38. Peters V, Becher D, Rehm BH. 2007. The inherent property of polyhydroxyalkanoate synthase to form spherical PHA granules at the cell poles: the core region is required for polar localization. J. Biotechnol. 132:238-245. (Pubitemid 47632859)
39. Peters V, Rehm BHA. 2008. Protein engineering of streptavidin for in vivo assembly of streptavidin beads. J. Biotechnol. 134:266-274.
40. Pollock JM, Andersen P. 1997. Predominant recognition of the ESAT-6 protein in the first phase of infection with Mycobacterium bovis in cattle. Infect. Immun. 65:2587-2592. (Pubitemid 27264082)
41. Ravn P, et al. 1999. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179:637-645. (Pubitemid 30016147)
42. Rebello H. 2007.FDA clears first of its kind suture made using DNA technology. P07-18.FDA, Washington, DC.
43. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. 2010. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13: 106-112.
44. Sambrook J, Fritsch EF, Maniatis T. 1989.Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
45. Scheerlinck JP, Greenwood DL. 2006. Particulate delivery systems for animal vaccines. Methods 40:118-124. (Pubitemid 44415503)
46. Sharp FA, et al. 2009. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 106:870-875.
47. Singh M, Chakrapani A, O'Hagan D. 2007. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6:797-808. (Pubitemid 47607854)
48. Skinner MA, et al. 2003. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108:548-555. (Pubitemid 36469693)
49. Soares AP, et al. 2008. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 180:3569-3577.
50. Tobin GJ, et al. 2008. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26:6189-6199.
51. Triccas JA, Sun L, Palendira U, Britton WJ. 2002. Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol. Cell Biol. 80:346-350. (Pubitemid 34779692)
52. Villatoro-Hernandez J, Montes-De-Oca-Luna R, Kuipers OP. 2011. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation. Expert Opin. Biol. Ther. 11:261-267.
53. Wedlock DN, et al. 2008. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clin. Vaccine Immunol. 15:765-772. (Pubitemid 351967029)
54. Wedlock DN, et al. 2005. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect. Immun. 73:3540-3546.
55. Williams SF, Martin DP, Horowitz DM, Peoples OP. 1999. PHA applications: addressing the price performance issue. I. Tissue engineering. Int. J. Biol. Macromol. 25:111-121. (Pubitemid 29301989)
56. Zhang Q, Zhong J, Huan L. 2011. Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Microbiol. Res. 166:111-120.